Background-Cardiac troponin T (cTnT) elevation is common and is a predictor of outcomes in patients with acute heart failure (AHF). The degree and progression of cTnT release during hospitalization of patients with AHF is unclear. We evaluated the incidence of cTnT release during AHF hospitalization and the relationship of cTnT release with outcomes. Methods and Results-The Placebo-controlled Randomized study of the selective A(1) adenosine receptor antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal funcTion (PROTECT) pilot study was a multicenter, double-blind study of patients with AHF. Measurements of cTnT were collected at randomization and days 2, 3, 4, and 7. Patients were classified on the basis of their serum cTnT levels at baseline: positive (Ͼ0.03 ng/mL), detectable (Ͼ0.01 ng/mL), and negative (Յ0.01 ng/mL). A detectable cTnT level developed during the study (after baseline) was classified as cTnT conversion: 288 patients were included; 172 (60%) patients had detectable cTnT levels and 97 (34%) had positive values (Ͼ0.03 ng/mL) at baseline. Of the 116 patients with negative troponin at baseline, 24 (21%) had elevated cTnT levels by day 7. On multivariable analysis, positive cTnT at baseline was an independent predictor of the composite end point of cardiovascular/renal rehospitalization or death at 60 days (hazard ratio, 1.84; 95% confidence interval, 1.04 -3.26; Pϭ0.036). Kaplan-Meier curves showed similar worse outcomes in patients with troponin conversion and positive troponin at baseline. Conclusions-There was a high prevalence of baseline cTnT elevation in this cohort; 21% of those negative at baseline converted to detectable levels by day 7. Positive troponin at baseline, and conversion to positive levels, were associated with worse outcomes at 60 days. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00328692 and NCT00354458. (Circ Heart Fail. 2011;4:724-732.)
A cute heart failure (AHF) is the most common cause of hospitalization in patients Ͼ65 years of age. 1 Despite advances in medical treatment, morbidity and mortality remain high. 2 The pathophysiologic mechanisms of acute decompensation and the persistently high short-term mortality may be related to abnormal hemodynamics, neurohormonal and inflammatory activation, volume overload of various etiologies, renal damage, and myocardial injury. [3] [4] [5] [6] Biological markers related to these mechanisms are therefore potentially useful in patients with AHF. Troponins I and T have been shown to be elevated in some ambulatory chronic heart failure (HF) patients and in patients with AHF and may be markers of poor prognosis. [7] [8] [9] [10] [11] [12] Clinical Perspective on p 732
The mechanism of troponin release in patients with HF is multifactorial. Abnormal hemodynamics with high left ventricular end-diastolic pressure and low aortic and coronary perfusion pressure, adrenergic stimulation, increased inflammatory cytokines, and excessive tachycardia due to arrhyth-mias such as rapid atrial fibrillation may all favor myocardial ischemia, loss of cell membrane integrity, and myocardial cell death with the mechanisms of necrosis and apoptosis. [13] [14] [15] Concomitant therapy with inotropic and vasodilating agents, especially when administered in combination or by use of agents that have both pharmacological effects, such as milrinone or levosimendan, may exacerbate all of these factors and lead to increased mortality. 16 Recent data suggest that elevated troponin concentrations are a predictor of poor outcomes in patients with AHF. 7 However, this study only assessed the role of troponin concentrations at the time of admission with respect to the prediction of in-hospital mortality. Serial measurements of troponin plasma levels during hospitalization were assessed in 2 studies to date, which demonstrated that troponin release commonly occurs and is associated with poor outcome in these clinical settings. In both studies, approximately 8 -10% of patients who were negative at baseline had an elevated troponin during hospitalization. 17, 18 The recently conducted PROTECT pilot study tested the effects of the selective adenosine A1 receptor antagonist rolofylline in patients with AHF and renal insufficiency. 19 In the present analysis, we evaluated the magnitude and time sequence of troponin release during initial hospitalization of patients with AHF and the relationship of this troponin release with subsequent short-term outcomes.
Methods

Trial Design and Patient Population
The PROTECT pilot study was a multicenter, double-blinded study, randomly assigning patients with AHF and renal insufficiency, defined as a creatinine clearance between 20 to 80 mL/min using the Cockcroft-Gault formula, 20 to intravenous rolofylline or placebo within 24 hours of admission. The details of the design, results, and conclusions of this trial have been previously published. 19 Eligible patients were Ն18 years of age and admitted with a primary diagnosis of AHF. A diagnosis of AHF required the following before random assignment: dyspnea at rest or minimal exertion, clinical evidence of fluid overload, and elevated natriuretic peptide levels (brain natriuretic peptide [BNP] Ͼ250 pg/mL or NT proBNP Ͼ1000 pg/mL). Exclusion criteria included systolic blood pressure Ͻ95 or Ͼ160 mm Hg; treatment with an inotropic agent, vasopressor, or vasodilator (except intravenous nitrates); mechanical support; acute contrast-induced nephropathy; resistant hypokalemia; severe pulmonary disease; previous cardiac transplantation; and evidence of acute coronary syndrome within 2 weeks of admission.
Serum Troponin T Measurements
Blood sample measurements of cardiac troponin T (cTnT) were collected at time of enrollment (day 1) and on days 2, 3, 4, and 7. Serum was stored at Ϫ7°C and shipped to the central core laboratory for analysis. Troponin levels were measured with a commercially available high sensitivity assay (Elecsys Troponin T STAT assay, Roche Diagnostics, Indianapolis, IN).
Patients were classified based on their serum cardiac troponin T levels at baseline: positive (Ͼ0.03 ng/mL), detectable (Ͼ0.01 ng/ mL), and negative (Յ0.01 ng/mL). Cardiac troponin conversion was defined as going from undetectable cTnT at baseline to having any detectable level during the hospitalization.
Plasma cTnT levels were measured after completion of the study, and patients' treatments or follow-ups were not influenced by their knowledge. Patient demographics, baseline characteristics, medical history, and medications were collected at time of random assignment.
End Points
The primary end point of the PROTECT trial was a composite trichotomous end point, designed to capture improvement of dyspnea and adverse events that occurred after admission, including worsening HF despite treatment or worsening renal function. Patient were classified as success, failure, or unchanged. Treatment success was defined as an improvement in dyspnea (reported by the patient, using a 7-point Likert scale, as moderately or markedly better compared with study start) determined at 24 and 48 hours after the start of study drug and not meeting criteria for treatment failure. Treatment failure was defined as death; worsening HF, defined as physiciandetermined assessment (based on history, physical examination, and chart review) of worsening symptoms or signs of HF occurring Ͼ24 hours after the start of study drug to day 7 or discharge, whichever occurred first; early HF readmission (occurring within 7 days of study drug initiation); or persistent renal impairment defined as an increase in serum creatinine of Ն0.3 mg/dL at day 7 and day 14.
Patients were classified as unchanged if neither criteria for success or failure were met.
In this post hoc analysis, the PROTECT primary end point was calculated on the basis of baseline cTnT level, using logistic regression with a 3-level outcome and the proportional odds assumption. We also evaluated the association of baseline cTnT level or conversion to detectable troponin T during hospitalization with the short-term end point of in-hospital worsening HF or death by day 7, based on troponin at baseline and conversion to any detectable level. Finally, we evaluated a composite of cardiovascular (CV)/renal rehospitalization or death by 60 days, based on troponin at baseline and conversion to any detectable level.
Statistical Analysis
Continuous variables with normal distribution were expressed as meanϮSD and medians (25th, 75th percentile) for other continuous variables. Comparisons of demographic and clinical baseline characteristics, medical history, and medications were evaluated by the Student t test for continuous variables and the 2 test for categorical variables. Multivariate analysis for the primary end point was performed using multiple logistic regression with positive and detectable troponin T variables analyzed as dichotomous variables. The model was adjusted for baseline clinical and laboratory characteristics. For the clinical end points, models were developed using candidate sets of predictor variables for possible model inclusion. The candidate variables represented a broad range of characteristics, which were classified as baseline characteristics, medical history, and laboratory values. A Cox proportional hazards backward selection algorithm was applied using a nominal 0.25 critical value for model inclusion. A candidate predictor was included in the model if it met the 0.25 critical significance value.
All reported probability values are 2-sided, and a probability value Ͻ0.05 was considered statistically significant.
The present study was conducted according to the principles stated in the Declaration of Helsinki. The study protocol was approved by the ethics committee and institutional review boards for each participating site, and all patients signed the informed consent form before participation in the study.
Results
Patient Population
Of 301 patients enrolled in the PROTECT pilot study, 288 had troponin T levels evaluable for inclusion into this study. There were no clinically important differences in the baseline characteristics of the excluded patients. The demographics and baseline characteristics of the population are shown in Table 1 . The mean age of the overall cohort was 70.6 years, and 59% were male. The clinical profile of the patients was similar to large acute HF registries. 10, 21 Most patients received optimal medical treatment, as recommended by international guidelines, before hospitalization. 22, 23 
Prevalence of Troponin Release
One hundred seventy-two (60%) patients had detectable (Ͼ0.01 ng/mL) cTnT levels, and 97 (34%) patients had positive values of cTnT (Ͼ0.03 ng/mL) at baseline. By day 7, 196 patients (68%) had detectable troponin T, and 92 (32%) remained negative.
Of the 116 patients with negative troponin T at baseline, 24 (21%) had a detectable cTnT level Ͼ0.01 ng/mL by day 7 (cTnT converters). The characteristics of those who were converters and those who did not convert are shown in Table  2 . There were no important differences in clinical characteristics between those who converted to any detectable levels of troponin T by day 7 compared with those who remained negative, except that patients with detectable troponin T by day 7 were more often diabetic (Pϭ0.046) and more often had an automatic implantable cardioverter-defibrillator without recent firing (Pϭ0.02). Of note, no patient with detectable cTnT at baseline dropped to having undetectable levels after baseline. There was no difference in worsening of creatinine clearance by day 7 in the converter group and no propensity of converters to have worse renal function. Additionally, we examined patients with coronary artery disease as a subset of interest, defined as patients with a history of myocardial infarction, coronary artery bypass surgery, or percutaneous coronary intervention. There was no difference in the incidence of troponin T release, conversion, or outcomes in this subset of patients compared with the overall study cohort.
There was no statistical evidence that rolofylline was associated with an increased risk of troponin T release compared with placebo. Although the numbers were small, the number of converters decreased as the dose of rolofylline increased, a finding that contradicts evidence suggesting adenosine A1 receptor stimulation is cardioprotective. 24
Outcomes
Composite Trichotomous End Point
In patients with either detectable troponin T or positive troponin T at baseline, there was no difference in the results observed for the trichotomous end point (Tables 3 and 4 ) compared with patients who were negative at baseline. Those patients who had positive troponin T levels at baseline or converted to any detectable level of troponin T were more often treatment failures and less often had treatment success ( Table 5) .
Short-Term End Point
On univariable analysis, any detectable troponin T at baseline was associated with a nearly 3-fold (hazard ratio [HR], 2.94; Pϭ0.03) increase in the risk of the short-term outcome of death or in-hospital worsening HF by day 7 (Table 3) .
Positive troponin T at baseline conferred a doubling risk of this end point, which occurred in 14% of patients with positive troponin T compared with 6% of patients with troponin T Ͻ0.03 ng/mL at baseline (HR, 2.4; Pϭ0.03; Table 4 ). On multivariable analysis, both detectable and positive troponin T at baseline indicated a greater risk for the short-term end point compared with those who were negative, but this difference did not achieve statistical significance (Table 6 ).
Those who converted to any detectable level of troponin T did not appear to have an increased risk of in-hospital mortality or worsening HF compared with those who were negative at baseline (Pϭ0.29).
CV/Renal Rehospitalization or Death at 60 Days
On univariable analysis, detectable troponin T (Ͼ0.01 ng/ mL) at baseline conferred a doubling of the risk (HR, 2.01; Pϭ0.005) for the composite end point of CV/renal rehospitalization or death at 60 days, compared with patients with negative troponin T at baseline. In particular, these patients had a 3.5-fold increased risk of death at 60 days (Pϭ0.023). Likewise, positive troponin T at baseline was associated with a doubling of the risk for cardiovascular/renal hospitalization or death at 60 days (HR, 2.19; PϽ0.001), with a 4-fold increased risk of death at 60 days (HR, 4.25; Pϭ0.001).
On multivariable analysis, positive levels of cardiac troponin T at baseline were confirmed to be an independent predictor of the composite end point of CV/renal rehospitalization or death at 60 days (HR, 1.84; 95% confidence interval [CI], 1.04 -3.26; Pϭ0.036), whereas detectable troponin T at baseline was not associated with a statistically significant increase in risk for this end point (HR, 1.23; 95% CI, 0.64 -2.35; Pϭ0.54, Table 7 ). In the group that converted to any detectable troponin T, there was a higher incidence of the composite end point compared with those who remained negative throughout hospitalization (33% versus 13%, Pϭ0.019), which was similar to those who were detectable at baseline (33%).
Kaplan-Meier curves showed similar worse outcomes in patients with troponin T conversion and positive troponin T levels at baseline, compared with those who were negative (Figures 1 and 2 ).
Discussion
To our knowledge, this study represents the largest cohort to date of AHF patients in which serial troponin T levels were correlated with outcomes. This analysis confirms that troponin T elevation at baseline is common in patients with AHF and mild-to-moderate renal dysfunction and is related to poor *Relative to negative troponin group. Models were run separately with "baseline troponin Ͼ0.01" and "baseline troponin Ͼ0.03." Because results for other variables were very similar in the 2 models, only those for the model with "baseline troponin Ͼ0.01" are presented.
†Linear dose trend in the order of placebo, 10 mg, 20 mg, and 40 mg.
prognosis. Univariate analysis showed the same high event rates in patients with positive and detectable cardiac troponin T levels at baseline. In multivariate analysis, only positive troponin T level was an independent predictor of mortality or CV/renal rehospitalization at 60 days. Conversion to any detectable level during hospitalization was also associated with statistically significant higher event rates at 60 days. There are several important findings of this analysis. First, there was a high prevalence (60%) of baseline troponin T elevation in this cohort. The reported prevalence has varied widely in other trials and registries; however, direct comparisons are difficult due to differences in the population being studied, different cutoff values, and variation in the assay being used. 7, 8, 17, 18, 21, 25 Second, 8% of the total cohort of patients (21% of those who were negative at baseline) converted to detectable levels of troponin T by day 7 of hospitalization. Finally, positive troponin T at baseline, and conversion to positive levels, were associated with worse outcomes at 60 days.
Cardiac troponin T is a marker of myocardial injury and the prognostic significance of elevated troponin levels in the evaluation and risk stratification of patients with AHF has been demonstrated. 11, 17, 26, 27 Several studies have shown that the release of troponin T is a predictor of short-and long-term prognosis in patients with AHF. 28 -32 In 84 872 subjects hospitalized for AHF, Peacock et al analyzed in-hospital outcomes and reported that a positive cardiac troponin was associated with greater in-hospital mortality (95% CI, 2.24 -2.89; PϽ0.001), a longer hospitalization, and greater use of resources. 7 In a large cohort of patients with stable chronic HF from the Valsartan Heart Failure Trial (Val-HeFT), detectable cardiac troponin T (Ͼ0.001 ng/mL) was found in 10.4% of 4053 patients and was associated with death (HR, 2.08; 95% CI, 1.72-2.52; PϽ0.001) and first hospitalization for HF (HR, 1.55; 95% CI, 1.25-1.93; PϽ0.001). 8 Other studies in stable outpatients with HF have shown a significant association between elevated levels of troponin and outcomes. 29 Of note is that there appeared to be similar risk of major cardiac events between converters and the patients with positive troponin T levels at baseline group. These elevations probably reflect ongoing injury after admission.
Our results suggest that postadmission cTnT measurements in addition to baseline measurements may be useful in understanding patients who have an unfavorable hospital course, particularly when those patients are initially troponin negative. The association between troponin T release and subsequent outcome suggests that myocardial injury occurs at a modest but not inconsequential rate and may persist well into the later stages of the hospitalization. Our study confirmed that the presence of troponin T at baseline and the persistent release of troponin T are correlated with a poor outcome.
Previous studies have shown the magnitude of troponin elevation is correlated with the severity of HF and worse outcomes. 8, [27] [28] [29] [30] Indeed, in our study the magnitude of troponin T at baseline predicted worse long-term outcomes. This evidence also suggests that a single measurement of cardiac *Relative to negative troponin group. Models were run separately with "baseline troponin Ͼ0.01" and "baseline troponin Ͼ0.03." Because results for other variables were very similar in the 2 models, only those for the model with "baseline troponin Ͼ0.01" are presented. troponin T at baseline is a strong predictor of risk for all-cause mortality and cardiovascular events, specifically worsening of HF.
Clinical Implications
Our study confirms that patients who present with positive troponin T levels at baseline may have a worse prognosis. Serial measurements may identify additional patients who may be at risk. Troponin may be an emerging biomarker useful for assessing safety and efficacy of HF therapies, and the finding that serial troponin release occurs throughout the hospitalization may provide a target for novel therapeutics to mitigate the risk of morbidity and mortality. Our findings suggest that myocardial injury is a frequent event in AHF patients and the release of troponin, particularly as it relates to current treatments and investigational therapies, should be examined. It is yet to be seen whether the greater sensitivity of new troponin assays will afford greater clinical utility in predicting outcomes, given the fact that Ͼ90% of acute decompensated HF (ADHF) patients have detectable troponin on these new assays.
Limitations
Our study was limited by the relatively modest number of patients, short follow-up period, and modest number of events. The small subgroup of patients with conversion from negative to positive troponin T after admission is of particular interest, but the association with poorer subsequent outcomes must be viewed as hypothesis-generating rather than conclusive. In addition, the analysis was carried out as a post hoc evaluation from the PROTECT pilot, of which the primary objective was to evaluate the effects of rolofylline on outcome in AHF with renal impairment. There could be a risk of overfitting the model, as the number of variables in the model was based on the primary end point of the trial. Our findings should be interpreted in the context of these limitations.
Conclusion
Our study confirms that troponin release is common in patients with AHF and cardiorenal impairment and that myocardial injury may continue to occur throughout hospitalization. In addition, our data show that positive troponin T at baseline is associated with worse outcomes at 60 days and conversion to any detectable level of troponin T may increase 60-day risk to the same extent as positive troponin T at baseline. These findings suggest that serial troponin measurements may be useful in assessing the safety and efficacy of existing and investigational therapies for AHF. Further prospective research is necessary to confirm these observations.
